1. Home
  2. IRIX vs MBRX Comparison

IRIX vs MBRX Comparison

Compare IRIX & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IRIDEX Corporation

IRIX

IRIDEX Corporation

HOLD

Current Price

$0.88

Market Cap

16.0M

Sector

Health Care

ML Signal

HOLD

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

HOLD

Current Price

$2.19

Market Cap

16.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRIX
MBRX
Founded
1989
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.0M
16.1M
IPO Year
1996
2016

Fundamental Metrics

Financial Performance
Metric
IRIX
MBRX
Price
$0.88
$2.19
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$61.00
AVG Volume (30 Days)
38.5K
279.8K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
51.85
N/A
EPS
N/A
N/A
Revenue
$41,593,000.00
N/A
Revenue This Year
$3.07
N/A
Revenue Next Year
$6.66
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$0.26
52 Week High
$1.65
$7.98

Technical Indicators

Market Signals
Indicator
IRIX
MBRX
Relative Strength Index (RSI) 21.30 42.85
Support Level $0.88 $2.00
Resistance Level $1.18 $2.58
Average True Range (ATR) 0.03 0.12
MACD -0.02 -0.01
Stochastic Oscillator 6.93 33.71

Price Performance

Historical Comparison
IRIX
MBRX

About IRIX IRIDEX Corporation

IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: